Follow BellaSeno for the latest company news, industry events, and regenerative medicine updates. Explore our latest media and announcements below.
Sign Up to Our Newsletter →
Following positive two-year human clinical data from its scaffold-guided regenerative program, BellaSeno has announced an exclusive global licensing agreement with Mentor Worldwide LLC, a Johnson & Johnson company.
This collaboration will bring together BellaSeno’s technology alongside the clinical, regulatory and commercial scale of one of the world’s leading healthcare companies. As breast aesthetics continues to evolve, there is growing demand for approaches that expand the range of solutions available to patients and surgeons. This collaboration will help accelerate the final clinical development of the breast scaffold platform as BellaSeno prepares for global market introduction.
BellaSeno Appoints Dr. Thomas Lingner as Chief Technology Officer and Inga Freyert as VP Quality and Regulatory Affairs
April 3, 2024
BellaSeno’s 3D-printed Resorbable Scaffold
March 5, 2024
Successfully Used in Critical-Size Large Segmental Radius Bone Defect
New investigator-initiated clinical trials
January 31, 2024
BellaSeno’s resorbable tissue regeneration scaffolds to be conducted in Europe
BellaSeno Presents Novel Production Workflow
October 30, 2023
Production Workflow for Customized, 3D-Printed Bone Scaffolds
Positive Follow-Up Data
September 5, 2023
BellaSeno Reports Positive One-Year Patient Follow-Up Data for Resorbable Breast and Pectus Excavatum Scaffolds
Granted Market Access
July 6, 2023
BellaSeno Granted Market Access in Europe for Custom-Made Bone and Pectus Excavatum Scaffolds
BellaSeno’s regenerative scaffold platform has been featured across international media, clinical discussions, and industry publications as interest grows in the future of soft-tissue restoration and scaffold-guided regeneration.
Deutscher Platz 5A
04103 Leipzig
Germany
4 Starling Street
Burliegh Heads
QLD, Australia, 4220
